Brokerages Set Moderna, Inc. (NASDAQ:MRNA) Price Target at $100.44

Moderna, Inc. (NASDAQ:MRNA) has been given an average rating of “Hold” by the nineteen analysts that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, thirteen have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $100.44.

Several analysts recently weighed in on MRNA shares. Oppenheimer lowered Moderna from an “outperform” rating to a “market perform” rating in a research note on Friday, September 13th. Jefferies Financial Group lowered shares of Moderna from a “buy” rating to a “hold” rating and decreased their price target for the company from $120.00 to $65.00 in a report on Friday, September 13th. Piper Sandler dropped their price objective on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, September 13th. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research note on Thursday, June 27th. Finally, Evercore ISI reiterated an “in-line” rating and issued a $120.00 price target on shares of Moderna in a research note on Thursday, June 27th.

Moderna Stock Down 3.3 %

Shares of MRNA opened at $61.07 on Friday. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. Moderna has a 12 month low of $61.03 and a 12 month high of $170.47. The firm’s 50 day moving average is $79.69 and its 200-day moving average is $108.29. The stock has a market capitalization of $23.40 billion, a PE ratio of -3.90 and a beta of 1.67.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, beating the consensus estimate of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm had revenue of $241.00 million for the quarter, compared to analyst estimates of $128.41 million. During the same period last year, the firm earned ($3.62) EPS. The business’s quarterly revenue was down 29.9% compared to the same quarter last year. Equities research analysts forecast that Moderna will post -9.86 EPS for the current year.

Insider Activity

In other news, CFO James M. Mock sold 689 shares of the firm’s stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $118.24, for a total value of $81,467.36. Following the completion of the sale, the chief financial officer now directly owns 7,269 shares in the company, valued at approximately $859,486.56. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Moderna news, CFO James M. Mock sold 689 shares of the stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $118.24, for a total value of $81,467.36. Following the transaction, the chief financial officer now owns 7,269 shares in the company, valued at $859,486.56. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at approximately $682,754. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 78,158 shares of company stock worth $9,259,012. Company insiders own 15.70% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in MRNA. Vanguard Group Inc. increased its holdings in Moderna by 15.1% during the 1st quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock worth $4,159,769,000 after purchasing an additional 5,129,800 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Moderna by 28.8% during the fourth quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock valued at $718,584,000 after acquiring an additional 1,614,460 shares during the last quarter. Capital World Investors boosted its position in Moderna by 0.5% in the first quarter. Capital World Investors now owns 3,648,117 shares of the company’s stock worth $388,743,000 after purchasing an additional 18,728 shares during the last quarter. Mawer Investment Management Ltd. increased its position in shares of Moderna by 6.7% during the 1st quarter. Mawer Investment Management Ltd. now owns 1,916,570 shares of the company’s stock valued at $204,230,000 after purchasing an additional 120,621 shares during the last quarter. Finally, Bellevue Group AG raised its stake in shares of Moderna by 27.6% during the 4th quarter. Bellevue Group AG now owns 1,908,420 shares of the company’s stock worth $189,792,000 after purchasing an additional 413,095 shares during the period. 75.33% of the stock is owned by institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.